Marketdash
Back to News

Five Stocks Making Waves After Earnings: Oracle Tumbles, HeartBeam Soars, and More

MarketDash Editorial Team
1 hour ago
Wednesday brought a mixed bag of earnings results that sent stocks in wildly different directions. Oracle plunged after hours despite beating estimates, HeartBeam nearly doubled on FDA clearance, and Planet Labs surged on strong guidance. Here's what moved the needle for investors.

Wednesday was one of those days where the market couldn't quite make up its mind. The S&P 500 and Nasdaq edged higher after the Federal Reserve delivered an expected 25 basis point rate cut, but the real story was the Fed's increasingly cautious tone about what comes next. While the Dow Jones Industrial Average climbed 1.05% to 48,057.75, the S&P 500 added nearly 0.7% to 6,886.68, and the Nasdaq inched up just 0.3% to 23,654.15, the action in individual stocks told a much more dramatic story.

The Federal Open Market Committee's revised guidance suggests they're pumping the brakes on future rate cuts, reflecting concerns about navigating a tricky economic environment with a softer labor market but persistent inflation. Translation: don't expect aggressive easing anytime soon.

But let's talk about the stocks that really grabbed attention from retail traders and investors on Wednesday.

Oracle Corp (ORCL): When Beating Estimates Isn't Enough

Oracle had what might charitably be called a rough evening. The stock closed Wednesday's regular session up 0.67% at $223.01, trading between an intraday high of $225.32 and a low of $217.58. Its 52-week range stretches from $345.72 down to $118.86, and unfortunately, investors seemed to think it might be heading back toward that lower end. After hours, the stock absolutely cratered, plummeting 11.56% to $197.23.

Why the carnage? Oracle reported second-quarter revenue of $16.06 billion, which came in slightly below estimates, even though adjusted earnings beat expectations at $2.26 per share. The company's cloud business is clearly booming with cloud revenue jumping 24% and cloud infrastructure soaring an impressive 68%, pushing total sales up 14% year-over-year. Remaining performance obligations surged to a staggering $523 billion, and Oracle even declared a 50-cent dividend.

But in the merciless world of tech earnings, "slightly below" on revenue is enough to trigger a selloff, even when everything else looks pretty good.

Synopsys, Inc. (SNPS): The Quiet Winner

While Oracle struggled, Synopsys had a much better day. The stock climbed 2.14% during regular trading to close at $475.83, hitting an intraday high of $478.65 and a low of $461.88. The 52-week range runs from $651.65 down to $365.74. In after-hours trading, shares rose another 2.3% to $486.99.

The semiconductor design software company beat fourth-quarter expectations with EPS of $2.90 and revenue of $2.26 billion. More importantly, Synopsys issued strong fiscal 2026 guidance, projecting adjusted EPS between $14.32 and $14.40 and revenue of $9.56 to $9.66 billion. When you beat estimates and raise guidance, investors tend to reward you. Simple as that.

HeartBeam, Inc. (BEAT): The Day's Biggest Rocket

If you want to talk about dramatic moves, HeartBeam takes the prize. The stock absolutely exploded, surging 92.43% to close at $1.55. It reached an intraday high of $1.79 and a low of $1.20, with a 52-week range from $3.48 down to $0.54. The shares did give back some gains in extended trading, sliding 13.33% to $1.34, but that's still an incredible one-day performance.

The catalyst? The FDA cleared HeartBeam's 12-lead ECG synthesis software, reversing a prior Non-Substantial Equivalence decision. This is genuinely interesting technology: it's cable-free and allows patients to capture a 12-lead ECG at home, with readings then reviewed by cardiologists. The clearance enables a limited U.S. launch in early 2026 and supports the company's plans to pursue a heart-attack detection indication and develop an extended-wear 12-lead patch.

For a small medical device company, FDA clearance is everything. The market's reaction reflected that reality.

Planet Labs PBC (PL): Satellite Imagery Shines

Planet Labs had a modest gain during regular trading, increasing 0.70% to close at $12.94. The stock recorded an intraday high of $13.24 and a low of $12.58, with a 52-week high of $16.78 and a low of $2.79. But after hours, things got interesting: the stock spiked 15.53% to $14.95.

The satellite imaging company posted third-quarter revenue of $81.25 million, up 33% and ahead of expectations. Its backlog jumped to $734 million, which tells you something about future demand. Planet Labs launched new satellites, hit breakeven on adjusted EPS, and boosted its full-year revenue outlook to $297 million to $301 million. When a growth company hits breakeven while accelerating revenue growth and raising guidance, that's the trifecta investors want to see.

Adobe, Inc. (ADBE): Steady as She Goes

Adobe had the most boring day of the bunch, which isn't necessarily a bad thing. The stock dipped slightly by 0.35% to close at $343.13, reaching an intraday high of $347.92 and a low of $340.57. The 52-week range runs from $552.30 down to $311.58.

Adobe beat expectations in the fourth quarter with earnings of $5.50 per share and revenue of $6.19 billion, up from $5.61 billion a year earlier. The company reported double-digit growth across major subscription segments and issued fiscal 2026 GAAP EPS guidance of $17.90 to $18.10, above analyst estimates. For a mature software giant, delivering consistent beats and solid guidance is exactly what shareholders want.

The mixed bag of results across these five stocks perfectly captures the current market environment: investors are selective, forward guidance matters enormously, and beating estimates doesn't guarantee a positive reaction if there's any hint of weakness. It's a market where the details matter, and where after-hours trading can completely change the narrative from the regular session.

Back to News

Five Stocks Making Waves After Earnings: Oracle Tumbles, HeartBeam Soars, and More

MarketDash Editorial Team
1 hour ago
Wednesday brought a mixed bag of earnings results that sent stocks in wildly different directions. Oracle plunged after hours despite beating estimates, HeartBeam nearly doubled on FDA clearance, and Planet Labs surged on strong guidance. Here's what moved the needle for investors.

Wednesday was one of those days where the market couldn't quite make up its mind. The S&P 500 and Nasdaq edged higher after the Federal Reserve delivered an expected 25 basis point rate cut, but the real story was the Fed's increasingly cautious tone about what comes next. While the Dow Jones Industrial Average climbed 1.05% to 48,057.75, the S&P 500 added nearly 0.7% to 6,886.68, and the Nasdaq inched up just 0.3% to 23,654.15, the action in individual stocks told a much more dramatic story.

The Federal Open Market Committee's revised guidance suggests they're pumping the brakes on future rate cuts, reflecting concerns about navigating a tricky economic environment with a softer labor market but persistent inflation. Translation: don't expect aggressive easing anytime soon.

But let's talk about the stocks that really grabbed attention from retail traders and investors on Wednesday.

Oracle Corp (ORCL): When Beating Estimates Isn't Enough

Oracle had what might charitably be called a rough evening. The stock closed Wednesday's regular session up 0.67% at $223.01, trading between an intraday high of $225.32 and a low of $217.58. Its 52-week range stretches from $345.72 down to $118.86, and unfortunately, investors seemed to think it might be heading back toward that lower end. After hours, the stock absolutely cratered, plummeting 11.56% to $197.23.

Why the carnage? Oracle reported second-quarter revenue of $16.06 billion, which came in slightly below estimates, even though adjusted earnings beat expectations at $2.26 per share. The company's cloud business is clearly booming with cloud revenue jumping 24% and cloud infrastructure soaring an impressive 68%, pushing total sales up 14% year-over-year. Remaining performance obligations surged to a staggering $523 billion, and Oracle even declared a 50-cent dividend.

But in the merciless world of tech earnings, "slightly below" on revenue is enough to trigger a selloff, even when everything else looks pretty good.

Synopsys, Inc. (SNPS): The Quiet Winner

While Oracle struggled, Synopsys had a much better day. The stock climbed 2.14% during regular trading to close at $475.83, hitting an intraday high of $478.65 and a low of $461.88. The 52-week range runs from $651.65 down to $365.74. In after-hours trading, shares rose another 2.3% to $486.99.

The semiconductor design software company beat fourth-quarter expectations with EPS of $2.90 and revenue of $2.26 billion. More importantly, Synopsys issued strong fiscal 2026 guidance, projecting adjusted EPS between $14.32 and $14.40 and revenue of $9.56 to $9.66 billion. When you beat estimates and raise guidance, investors tend to reward you. Simple as that.

HeartBeam, Inc. (BEAT): The Day's Biggest Rocket

If you want to talk about dramatic moves, HeartBeam takes the prize. The stock absolutely exploded, surging 92.43% to close at $1.55. It reached an intraday high of $1.79 and a low of $1.20, with a 52-week range from $3.48 down to $0.54. The shares did give back some gains in extended trading, sliding 13.33% to $1.34, but that's still an incredible one-day performance.

The catalyst? The FDA cleared HeartBeam's 12-lead ECG synthesis software, reversing a prior Non-Substantial Equivalence decision. This is genuinely interesting technology: it's cable-free and allows patients to capture a 12-lead ECG at home, with readings then reviewed by cardiologists. The clearance enables a limited U.S. launch in early 2026 and supports the company's plans to pursue a heart-attack detection indication and develop an extended-wear 12-lead patch.

For a small medical device company, FDA clearance is everything. The market's reaction reflected that reality.

Planet Labs PBC (PL): Satellite Imagery Shines

Planet Labs had a modest gain during regular trading, increasing 0.70% to close at $12.94. The stock recorded an intraday high of $13.24 and a low of $12.58, with a 52-week high of $16.78 and a low of $2.79. But after hours, things got interesting: the stock spiked 15.53% to $14.95.

The satellite imaging company posted third-quarter revenue of $81.25 million, up 33% and ahead of expectations. Its backlog jumped to $734 million, which tells you something about future demand. Planet Labs launched new satellites, hit breakeven on adjusted EPS, and boosted its full-year revenue outlook to $297 million to $301 million. When a growth company hits breakeven while accelerating revenue growth and raising guidance, that's the trifecta investors want to see.

Adobe, Inc. (ADBE): Steady as She Goes

Adobe had the most boring day of the bunch, which isn't necessarily a bad thing. The stock dipped slightly by 0.35% to close at $343.13, reaching an intraday high of $347.92 and a low of $340.57. The 52-week range runs from $552.30 down to $311.58.

Adobe beat expectations in the fourth quarter with earnings of $5.50 per share and revenue of $6.19 billion, up from $5.61 billion a year earlier. The company reported double-digit growth across major subscription segments and issued fiscal 2026 GAAP EPS guidance of $17.90 to $18.10, above analyst estimates. For a mature software giant, delivering consistent beats and solid guidance is exactly what shareholders want.

The mixed bag of results across these five stocks perfectly captures the current market environment: investors are selective, forward guidance matters enormously, and beating estimates doesn't guarantee a positive reaction if there's any hint of weakness. It's a market where the details matter, and where after-hours trading can completely change the narrative from the regular session.